| Literature DB >> 34446011 |
Thi Mui Pham1, Hannan Tahir2, Janneke H H M van de Wijgert2,3, Bastiaan R Van der Roest2, Pauline Ellerbroek4, Marc J M Bonten2,5, Martin C J Bootsma2,6, Mirjam E Kretzschmar2.
Abstract
BACKGROUND: Emergence of more transmissible SARS-CoV-2 variants requires more efficient control measures to limit nosocomial transmission and maintain healthcare capacities during pandemic waves. Yet the relative importance of different strategies is unknown.Entities:
Mesh:
Year: 2021 PMID: 34446011 PMCID: PMC8390112 DOI: 10.1186/s12916-021-02060-y
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Fig. 1Schematics for agent-based model. A Diagram of the agent-based model including the agents in the main environment (hospital) and community importations. The hospital population is divided into healthcare workers (nurses and doctors) and patients. Patients may be admitted from the community either with moderate (red) or severe (dark red) COVID-19 symptoms or for non-COVID reasons. Patients may be in a pre-symptomatic stage (light red) when hospitalized to non-COVID wards. Healthcare workers may get infected in the community (red dashed line). B Disease progression diagram. Individuals are in either of the following categories: susceptible (S), asymptomatically infected (I), pre-symptomatically infected (I),moderately infected (I), severely infected (I) and recovered (R). Infected individuals are assumed to be infectious following a time-varying infectiousness presented in C. C Probability density of infectiousness of an infected individual and incubation period over time since infection
Parameter values for the agent-based model
| Symbol | Description | Distribution/valuea | Source | |
|---|---|---|---|---|
| Incubation period | Time between infection and symptom onset | Gamma distribution Shape = 5.807 Scale = 0.948 Mean = 5.510 SD = 2.284 | Lauer et al. [ | |
| Generation time | Time between becoming infected and subsequent onward transmission events | Weibull distribution Shape = 2.826 Scale = 6.839 Mean = 6 | Grassly et al. [ | |
| Proportion of asymptomatic infections among infected patients | 20% | Buitraga-Garcia et al. [ | ||
| Proportion of asymptomatic infections among infected HCWs | 31% | Buitraga-Garcia et al. [ | ||
| Proportion of severe symptomatic individuals | Proportion of exposed individuals that will develop severe symptoms | 20% | Wu et al. [ | |
| Reproduction number of asymptomatic infectees for wild-type variant | Mean number of infections caused by an individual asymptomatically infected with the wild-type SARS-CoV-2 variant | 0.5 | Calibrated to UMCU data | |
| Reproduction number of symptomatic infectees for wild-type variant | Mean number of infections caused by an individual symptomatically infected with the wild-type SARS-CoV-2 variant | 1.25 | Calibrated to UMCU data | |
| Reproduction number of asymptomatic infectees for new virus variant | Mean number of infections caused by an individual asymptomatically infected with the SARS-CoV-2 variant | 0.8 (1.95) | Based on | |
| Reproduction number of symptomatic infectees for new virus variant | Mean number of infections caused by an individual symptomatically infected with the SARS-CoV-2 variant | 1.95 | Based on | |
| Maximum sensitivity of diagnostic PCR test | 93.1% (79%) | Grassly et al. [ | ||
| Proportion of HCWs that work in the same ward as during their previous shift | 95% (baseline) 100% (intervention) | Assumed | ||
| PPE effectiveness | Reduction in infectiousness upon contact between an infected and susceptible individual (includes PPE efficacy and adherence) | 90% (50%, 70%) | Suzuki et al. [ | |
| Isolation period for HCWs | Amount of time HCWs have to isolate after symptom onset or after being detected by screening or contact tracing | 7 days | Assumed | |
| Recovery time for asymptomatic infection | Mean duration of an asymptomatic infection | 14 days Sensitivity analysis: Unif(9, 19) | Assumed | |
| Recovery time for symptomatic (moderate, severe) infection | Mean duration of a symptomatic infection | 14 days (moderate) 35 days (severe) Sensitivity analysis: Unif(9, 19) Unif(30, 40) | Liu et al. [ | |
| LoS of non-COVID patients in ICU | Lognormal meanlog = 0.37 sdlog = 0.82 Mean = 1.45 days sd = 2.27 | Fitted distributions to UMCU data from 2014-2017 | ||
| LoS of non-COVID patients in normal ward | Weibull Shape = 0.92 Scale = 4.18 Mean = 4.35 days | Fitted distributions to UMCU data from 2014-2017 | ||
| LoS of moderately infected patients | Gamma Shape = 1.88 Rate = 0.25 Mean = 31.8 days sd = 30.08 | Fitted distributions to UMCU data from 2020 | ||
| LoS of severely infected patients | Gamma Shape = 1.59 Rate = 0.05 Mean = 7.52 days sd = 636 | Fitted distributions to UMCU data from 2020 |
aValues given are fixed in the simulations. Values in brackets were used in sensitivity analyses
Fig. 2Comparison of the scenarios with the wild-type and a more transmissible SARS-CoV-2 variant. Both scenarios assume 90% effective PPE use in COVID wards. For the wild-type scenario (black), model simulations were performed with RS = 1.25 (reproduction number of symptomatically infected individuals) and RA = 0.5 (reproduction number of asymptomatically infected individuals). For the baseline scenario (blue), model simulations were performed with RS = 1.95 and RA = 0.8 (with 56% higher transmissibility with respect to the wild-type SARS-CoV-2 variant). Horizontal dashed lines represent a reproduction number of 1. Summary statistics were calculated for 100 simulations. A Simulated mean number of beds occupied by patients in COVID wards per day (black curve) and 95% uncertainty interval (grey shaded area). Red points represent real-life data on the daily number of beds occupied by COVID-19 patients at the UMCU between 27 February and 24 August 2020. B Number of nosocomial transmissions as predicted by the models. Full rectangular bar height represents the mean total number of nosocomial transmissions during the whole study period. Grey error bars represent 95% uncertainty intervals. Patients acquiring a SARS-CoV-2 nosocomial infection may be diagnosed in the hospital (due to symptom onset during hospital stay or detection by an intervention) or discharged to the community in a pre-symptomatic or asymptomatic state. Rectangular bars with black borders represent mean number of individuals (patients and HCWs) infected with SARS-CoV-2 and diagnosed in the hospital. Lighter rectangular bars represent the remaining mean number of patients discharged to community undiagnosed. C Violin and box plots of the overall effective reprduction numbers (R, for pre-/symptomatic and asymptomatic patients and HCWs combined) for the nosocomial spread in the wild-type and baseline scenario. D Violin and box plots of R for the nosocomial spread in the wild-type and baseline scenario (separate values for pre-/symptomatic and asymptomatic individuals). Since HCWs are assumed to immediately self-isolate upon symptom onset, the reproduction number is assigned to the pre-symptomatic state
Overview of all simulated scenarios. The main characteristics of the scenarios simulated in our agent-based model are presented
Fig. 3Effective reproduction numbers for the nosocomial spread of the SARS-CoV-2 variant for each simulation scenario. Results shown are based on R = 1.95 and R = 0.8 (reproduction numbers for the SARS-CoV-2 variant with 56% higher transmissibility with respect to the wild-type SARS-CoV-2 variant). Horizontal dashed lines represent a reproduction number of 1. Summary statistics were calculated for 100 simulations. A For each intervention scenario, violin and boxplots of the overall effective reproduction numbers (for pre-/symptomatic and asymptomatic patients and HCWs combined) are shown. B For each intervention scenario, violin and boxplots of the effective reproduction numbers for pre-/symptomatic and asymptomatic individuals are shown. Since HCWs are assumed to immediately self-isolate upon symptom onset, the reproduction number is assigned to the pre-symptomatic state. For screening every 3 days and 7-day contact tracing prior to symptom onset of SARS-CoV-2 infected HCWs, we considered two different test sensitivity scenarios: time-invariant perfect test sensitivity (perfect sens) and time-varying test sensitivity.
Fig. 4Number of nosocomial transmissions of the SARS-CoV-2 variant for each simulation scenario. Results shown are based on R = 1.95 and R = 0.8 (reproduction numbers for the SARS-CoV-2 variant with 56% higher transmissibility with respect to the wild-type SARS-CoV-2 variant). Summary statistics were calculated for 100 simulations. The full rectangular bar height represents the mean total number of nosocomial transmissions during the whole study period. The grey error bars represent the corresponding 95% uncertainty intervals. Patients that acquire a SARS-CoV-2 nosocomial infection may be diagnosed in the hospital (due to symptom onset during hospital stay or due to detection by an intervention) or discharged to the community in a pre-symptomatic or asymptomatic state. The rectangular bars with the black border represent the mean number of individuals (patients and HCWs) infected with SARS-CoV-2 and diagnosed in the hospital. The lighter rectangular bars represent the remaining mean number of patients discharged to community undiagnosed. For screening every 3 days and 7-day contact tracing, we considered two different test sensitivity scenarios: time-invariant perfect test sensitivity (perfect sens) and time-varying imperfect test sensitivity.
Fig. 5Number of nosocomial infections among patients and HCWs over time for all simulation scenarios with the SARS-CoV-2 variant. Results shown are based on R = 1.95 and R = 0.8 (reproduction numbers for the SARS-CoV-2 variant with 56% higher transmissibility with respect to the wild-type SARS-CoV-2 variant). For each scenario, the 7-day moving average of the mean prevalence (over 100 simulation runs) is shown. A Number of hospital-acquired infections among patients. B Number of hospital-acquired infections among HCWs. For screening every 3 days and contact tracing 7 days prior to symptom onset of SARS-CoV-2 infected HCWs, we considered two different test sensitivity scenarios: time-invariant perfect test sensitivity (perfect sens) and time-varying imperfect test sensitivity
Fig. 6Daily percentage of absent HCWs during the hospital epidemic for each simulation scenario. Results shown are based on R = 1.95 and R = 0.8 (reproduction numbers for the SARS-CoV-2 variant with 56% higher transmissibility with respect to the wild-type SARS-CoV-2 variant). The 7-day moving average of the mean percentage (over 100 simulation runs) of HCWs absent from work due to symptom onset or a detected SARS-CoV-2 infection screening or contact tracing is shown. For screening every 3 days and contact tracing 7 days prior to symptom onset of SARS-CoV-2 infected HCWs, we considered two different test sensitivity scenarios: time-invariant perfect test sensitivity (perfect sens) and time-varying imperfect test sensitivity
Fig. 7Positivity rates over time for screening interventions. Results shown are based on R = 1.95 and R = 0.8 (reproduction numbers for the SARS-CoV-2 variant with 56% higher transmissibility with respect to the wild-type SARS-CoV-2 variant). Positivity rates were calculated by the number of positive detected HCWs among the number of tested HCWs using data of all simulation runs combined (points). The shaded regions represent the 95% Bayesian beta-binomial credibility intervals. HCWs who developed symptoms prior to the day of testing were not included in the positivity rate as we assume that they were already correctly identified. A Screening every 3 days with time-invariant perfect test sensitivity. B Screening every 3 days with time-varying imperfect test sensitivity. C Screening every 7 days with time-varying test sensitivity
Fig. 8Positivity rates over time for contact tracing interventions. Results shown are based on R = 1.95 and R = 0.8 (reproduction numbers for the SARS-CoV-2 variant with 56% higher transmissibility with respect to the wild-type SARS-CoV-2 variant). The positivity rate is computed by the percentage of positive tested contacts among all traced contacts using data of all 100 simulation runs merged. Positivity rates are assigned to the day of symptom onset of the index case, i.e., HCW that developed symptoms due to a SARS-CoV-2 infection. Traced contacts who developed symptoms due to a SARS-CoV-2 infection are excluded from contact tracing as we assume that they are always correctly identified. The plot shows the 7-day moving average (coloured line) and the 95% Bayesian beta-binomial confidence interval (shaded area). A Tracing contacts of symptomatically infected HCWs of the last 2 days before symptom onset using a diagnostic test with perfect test sensitivity. B Tracing contacts of symptomatically infected HCWs of the last 2 days before symptom onset with testing 5 days after contact with the index case assuming time-varying test sensitivity. C Tracing contacts of symptomatically infected HCWs of the last 7 days before symptom onset with testing 5 days after contact with the index case assuming time-varying test sensitivity